Your session is about to expire
← Back to Search
Ipatasertib + Docetaxel for Non-Small Cell Lung Cancer (Ipat-Lung Trial)
Ipat-Lung Trial Summary
This trial is for patients with NSCLC who have failed or are intolerant to 1st line immunotherapy. It is a combination of ipatasertib (a novel adenosine triphosphate [ATP]-competitive inhibitor) and taxane (e.g. docetaxel).
Ipat-Lung Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowIpat-Lung Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 242 Patients • NCT04177108Ipat-Lung Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I have or had inflammatory bowel disease or active bowel inflammation.You have a measurable disease according to specific guidelines.I agree not to donate sperm during and for 3 months after the study.I have severe side effects from my first immunotherapy.I, or my legal representative, can understand the study and agree to sign the consent form.My doctor expects me to live for at least 12 more weeks.I have high cholesterol or triglycerides that are not under control.My cancer has a mutation that can be treated with specific drugs.You have had an allergic reaction to taxanes in the past.I am receiving my first treatment with PD1/PD-L1 inhibitors, alone or with chemotherapy.My advanced lung cancer didn't respond or couldn't tolerate first-line immunotherapy.I haven't had cancer treatment in the last 14 days, except possibly for palliative care.I am fully active or can carry out light work.I currently have lung inflammation.I have a condition that affects my ability to absorb nutrients or swallow pills.I have not had a heart attack or heart disease symptoms in the last 6 months.I am on medication for irregular heartbeats.I am currently being treated for HIV, hepatitis B, or hepatitis C.I have had cancer spread to the lining of my brain and spinal cord.I haven't had major surgery in the last 4 weeks that would interfere with taking the study drug.I have diabetes that requires insulin treatment.My lung cancer is a mix of small cell and non-small cell types.I am not on any strong medication that affects liver enzymes.I have brain metastasis that is not under control.I do not have any uncontrolled illnesses.My organs are working well.I have a history of serious lung disease.I have fluid buildup that isn't being managed.
- Group 1: Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any adverse effects associated with Ipatasertib?
"Due to the lack of evidence suggesting efficacy, our team at Power assigned Ipatasertib a safety rating of 2 out of 3. However, there is some data indicating its safety in Phase 2 trials."
What is the capacity of this clinical trial in terms of participant numbers?
"Affirmative. Clinicaltrials.gov displays that this medical study, first published on September 14th 2021, is still enrolling patients. 60 participants are needed to be drawn from 2 clinical sites."
Is the enrollment period currently open for this investigation?
"Affirmative. Clinicaltrials.gov has documented that this clinical trial, which was initially posted on September 14th 2021, is still actively searching for participants. Around 60 individuals need to be recruited from 2 separate research sites."
Share this study with friends
Copy Link
Messenger